OncoMatch/Clinical Trials/NCT07645625
Pembrolizumab Registry for Outcomes and Treatment Evaluation in Cervical Cancer
Is NCT07645625 recruiting? Yes, currently enrolling (Sep 2026). This Phase 4 trial studies Early discontinuation of Pembrolizumab with or without Bevacizumab for cervical cancer.
Treatment: Early discontinuation of Pembrolizumab with or without Bevacizumab
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Cancer type
Cervical Cancer
Disease stage
Required: Stage PERSISTENT, IV
Persistent, recurrent, or metastatic cervical cancer
Demographics
Prior therapy
Must have received: anti-PD-1 therapy (pembrolizumab)
commencing treatment or currently treated with a pembrolizumab containing regimen
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07645625 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received anti-PD-1 therapy.
What disease stage is eligible?
Stage PERSISTENT or IV is required.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages